A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome

Cancer Immunol Immunother. 2016 Jun;65(6):765-7. doi: 10.1007/s00262-016-1835-4. Epub 2016 Apr 11.

Authors

Elizabeth Hansen¹, Deepak Sahasrabudhe², Lynn Sievert²

Affiliations

¹ University of Rochester Medical Center, 601 Elmwood Avenue, Box 617, Rochester, NY, 14642, USA. [email protected].
² University of Rochester Medical Center, 601 Elmwood Avenue, Box 617, Rochester, NY, 14642, USA.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Diabetes Mellitus, Type 1 / diagnosis
Diabetes Mellitus, Type 1 / etiology*
Diabetes Mellitus, Type 1 / therapy
Disease Management
Humans
Insulins / administration & dosage
Insulins / therapeutic use
Male
Melanoma / complications
Melanoma / diagnosis
Melanoma / drug therapy
Melanoma, Cutaneous Malignant
Middle Aged
Molecular Targeted Therapy / adverse effects
Patient Outcome Assessment
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Skin Neoplasms
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Insulins
Programmed Cell Death 1 Receptor
pembrolizumab